Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Lowers serum urate through uricosuric activity by reducing renal tubular urate reabsorption; published pharmacology also describes non-purine xanthine oxidase inhibition. The relative contribution of each action depends on the source and product.
Indications / reported uses
Treatment of chronic hyperuricaemia and gout in selected patients where authorised, generally when first-line urate-lowering therapy is unsuitable or ineffective. It is not for treatment of an acute gout attack. Use is limited in many jurisdictions because of serious hepatotoxicity, including reports of fatal liver injury.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Benzbromarone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Benzbromarone Permitted Daily Exposure (PDE) report (the Benzbromarone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Benzbromarone Occupational Exposure Limit (OEL) report (the Benzbromarone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.